


FMF-01-086-2Chemical Formula: C₃₀H₂₇N₇O₃

Molecular Weight: 533.59

Category	Parameter	Description
Compound	Name	FMF-01-086-2
	Citation	Bioorg Med Chem Lett. 2017 Sep 15;27(18):4405-4408. https://doi.org/10.1016/j.bmcl.2017.08.016
	Chemical descriptors	CC1=CC2=C(N(C)C(N=C(NC3=CC=C(NC(C4=CC=C(NC(C=C)O)C=C4)O)C=C3)N=C5)C5N(C)C2=O)C=C1
	Chemical name	4-acrylamido- <i>N</i> -(4-((5,8,11-trimethyl-6-oxo-6,11-dihydro-5 <i>H</i> -benzo[<i>e</i>]pyrimido[5,4- <i>b</i>][1,4]diazepin-2-yl)amino)phenyl)benzamide
	Entries in chemical databases	
	Availability	
<i>In vitro</i> profiling	Papers that use the compounds	
	Additional comments	
	Target (potency)	Aurora A (IC ₅₀ = 44 nM +/- 4.5 nM)
	Target (potency)	Aurora B (IC ₅₀ = 29 nM +/- 2.0 nM)
	Target (potency)	Aurora C (IC ₅₀ = 63 nM +/- 8.1 nM)
	Selectivity	Exclusively on-target activity detected by KINOMEScan® at 1 μM compound concentration. PLK4 biochemical IC ₅₀ = 43 nM
	Potential reactivity	Cysteine reactive
	SAR	Described in paper
	Mechanism of inhibition	Reversible
	Structure of target-probe complex	

<p>Cellular profiling</p>	<p>Validation of cellular target</p> <p>Validation of cellular specificity</p>	<p>Dose dependent inhibition of pAurora A (Aurora A substrate) and pH3 S10 (Aurora B substrate) in HCT116 cells. Effects on cell cycle consistent with selective on-target inhibition.</p>
<p>Pharmacodynamics</p>	<p>n/a</p>	
<p>Pharmacokinetics</p>	<p>n/a</p>	
<p>Synthetic scheme</p>	<p>Intermediate 1</p> <p>Intermediate 2</p> <p>Intermediate 3</p> <p>Intermediate 4</p> <p>Intermediate 5</p> <p>Intermediate 6</p> <p>Compound 1</p>	